Ibio, Inc.

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Announces $26 Million Private Placement